Most people first hear about “eating for your genotype” through the popular blood-type diet. In simple terms, it suggests ...

Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...

Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

Gut health is gaining attention after insights from celebrity doctor Steven Gundry highlighted how diet, fasting and simple ...

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

Researchers demonstrated that newly developed molecules designed to block an immune checkpoint can trigger a powerful immune response against tumors. Scientists at MIT and Stanford University have ...

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...

Why Dr. Steven Gundry's Probiotic, Prebiotic & Postbiotic "Triple-Action" Formula is Transforming Gut Health and Boosting Overall Wellness*✝LOS ...

The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults and children aged ...

Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. The stock was up 78% to $15.60 on Wednesday and was briefly paused ...